NZ530951A - Pyrimidine derivatives having HIV replication inhibiting properties - Google Patents

Pyrimidine derivatives having HIV replication inhibiting properties

Info

Publication number
NZ530951A
NZ530951A NZ530951A NZ53095102A NZ530951A NZ 530951 A NZ530951 A NZ 530951A NZ 530951 A NZ530951 A NZ 530951A NZ 53095102 A NZ53095102 A NZ 53095102A NZ 530951 A NZ530951 A NZ 530951A
Authority
NZ
New Zealand
Prior art keywords
6alkyl
cyano
formula
nr9r10
substituted
Prior art date
Application number
NZ530951A
Other languages
English (en)
Inventor
Jerome Emile George Guillemont
Patrice Palandjian
Jonge Marc Rene De
Lucien Maria Henricus Koymans
Hendrik Maarten Vinkers
Frederik Frans Desire Daeyaert
Jan Heeres
Aken Koen Jeanne Alfons Van
Paulus Joannes Lewi
Paul Adriaan Jan Janssen
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26076978&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ530951(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NZ530951A publication Critical patent/NZ530951A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/12—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ530951A 2001-08-13 2002-08-09 Pyrimidine derivatives having HIV replication inhibiting properties NZ530951A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01203090 2001-08-13
EP02077748 2002-06-10
PCT/EP2002/008953 WO2003016306A1 (en) 2001-08-13 2002-08-09 Hiv inhibiting pyrimidines derivatives

Publications (1)

Publication Number Publication Date
NZ530951A true NZ530951A (en) 2005-10-28

Family

ID=26076978

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ530951A NZ530951A (en) 2001-08-13 2002-08-09 Pyrimidine derivatives having HIV replication inhibiting properties

Country Status (37)

Country Link
US (8) US7125879B2 (forum.php)
EP (3) EP3808743B1 (forum.php)
JP (4) JP2005507380A (forum.php)
KR (2) KR100969273B1 (forum.php)
CN (2) CN101816658B (forum.php)
AP (1) AP1610A (forum.php)
AR (1) AR036387A1 (forum.php)
AT (1) ATE517891T1 (forum.php)
AU (1) AU2002329238C1 (forum.php)
BE (3) BE2012C020I2 (forum.php)
BR (3) BR122015032641B1 (forum.php)
CA (1) CA2452217C (forum.php)
CY (4) CY1112331T1 (forum.php)
DE (1) DE122012000038I1 (forum.php)
DK (2) DK1419152T3 (forum.php)
EA (1) EA006656B1 (forum.php)
EG (1) EG24684A (forum.php)
ES (3) ES2799408T3 (forum.php)
FR (3) FR12C0035I2 (forum.php)
HR (3) HRP20120265B1 (forum.php)
HU (5) HU231274B1 (forum.php)
IL (2) IL160328A0 (forum.php)
JO (1) JO3429B1 (forum.php)
LT (2) LT3808743T (forum.php)
LU (2) LU92001I2 (forum.php)
MX (1) MXPA04001401A (forum.php)
MY (1) MY189572A (forum.php)
NO (3) NO327639B1 (forum.php)
NZ (1) NZ530951A (forum.php)
OA (1) OA12652A (forum.php)
PA (1) PA8552901A1 (forum.php)
PL (2) PL216398B1 (forum.php)
PT (1) PT1419152E (forum.php)
SI (2) SI3808743T1 (forum.php)
UA (1) UA78221C2 (forum.php)
WO (1) WO2003016306A1 (forum.php)
ZA (1) ZA200401159B (forum.php)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US8101629B2 (en) * 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
IL164006A0 (en) 2002-03-13 2005-12-18 Janssen Pharmaceutica Nv Inhibitors of histone deacetylase
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
IL166241A (en) 2002-07-29 2011-12-29 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds for use in the treatment of autoimmune diseases
CN101481356B (zh) * 2002-08-09 2012-07-11 詹森药业有限公司 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
JP2006508997A (ja) * 2002-11-28 2006-03-16 シエーリング アクチエンゲゼルシャフト Ｃｈｋ−、Ｐｄｋ−およびＡｋｔ−阻害性ピリミジン、それらの製造および薬剤としての使用
US7585861B2 (en) * 2003-02-07 2009-09-08 Janssen Pharmaceutica, N.V. HIV inhibiting 1,2,4-triazines
US20070021449A1 (en) * 2003-02-07 2007-01-25 Jan Heeres Pyrimidine derivatives for the prevention of hiv infection
CL2004000303A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
ES2667668T3 (es) 2003-07-17 2018-05-14 Janssen Sciences Ireland Uc Procedimiento para preparar partículas que contienen un antiviral
US7122542B2 (en) 2003-07-30 2006-10-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
NZ585188A (en) * 2003-08-15 2011-09-30 Novartis Ag 2,4-Pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
TWI365744B (en) * 2003-09-03 2012-06-11 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
WO2005028479A2 (en) * 2003-09-25 2005-03-31 Janssen Pharmaceutica N.V. Hiv replication inhibiting purine derivatives
US7456176B2 (en) 2004-04-08 2008-11-25 Targegen, Inc. Benzotriazine inhibitors of kinases
SG156687A1 (en) 2004-07-28 2009-11-26 Janssen Pharmaceutica Nv Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
JP5031564B2 (ja) 2004-08-10 2012-09-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖ抑制１，２，４−トリアジン−６−オン誘導体
US7947721B2 (en) 2004-08-25 2011-05-24 Ardes Biosciences Inc. S-triazolyl α-mercaptoacetanilides as inhibitors of HIV reverse transcriptase
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
RS51923B2 (sr) * 2004-09-02 2022-05-31 Janssen Pharmaceutica Nv So 4[[4-[[4-(2-cijanoetenil)-2,6-dimetilfenil]amino]-2- pirimidinil]amino]benzonitrila
WO2006024668A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
ATE550074T1 (de) * 2004-09-02 2012-04-15 Janssen Pharmaceutica Nv Fumarat aus 4-((4-((4-(2-cyanoethenyl)-2,6- dimethylphenyl amino -2-pyrimidinyl amino benzonitril
WO2006024667A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
UA92467C2 (ru) * 2004-09-02 2010-11-10 Янссен Фармацевтика Н.В. Гидрохлорид 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
WO2006034338A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
TW200624427A (en) 2004-09-20 2006-07-16 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
TW200626154A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
AR051094A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
MX2007003321A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
EP1804799B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
TW200626592A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
ATE520672T1 (de) * 2004-09-30 2011-09-15 Tibotec Pharm Ltd Hiv-hemmende 5-carbo- oder heterozyklisch substituierte pyrimidine
BRPI0516748B8 (pt) * 2004-09-30 2021-05-25 Janssen Sciences Ireland Uc pirimidinas 5-substituídas inibidoras de hiv e composição farmacêutica que as compreende
ES2371923T3 (es) 2004-09-30 2012-01-11 Tibotec Pharmaceuticals 5-heterociclil-pirimidinas que inhiben el vih.
SI1814878T1 (sl) 2004-11-24 2012-06-29 Rigel Pharmaceuticals Inc Spojine spiro-2,4-pirimidindiamina in njihova uporaba
SI1856135T1 (sl) 2005-01-19 2010-04-30 Rigel Pharmaceuticals Inc Predzdravila 2,4-pirimidindiaminskih spojin in njihove uporabe
US7906511B2 (en) 2005-03-31 2011-03-15 Santen Pharmaceutical Co., Ltd. Cyclic compound having pyrimidinylalkylthio group
TW201414495A (zh) 2005-04-04 2014-04-16 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
WO2006122003A2 (en) 2005-05-05 2006-11-16 Ardea Biosciences, Inc. Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv
RU2458056C2 (ru) * 2005-05-26 2012-08-10 Тиботек Фармасьютикалз Лтд Способ получения 4-(1,6-дигидро-6-оксо-2-пиримидинил)амино-бензонитрила
US8541457B2 (en) 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
NZ563454A (en) 2005-06-08 2011-03-31 Rigel Pharmaceuticals Inc 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
RU2597364C2 (ru) 2005-11-01 2016-09-10 Таргеджен, Инк. Би-арил-мета-пиримидиновые ингибиторы киназ
CN101370790B (zh) 2006-01-19 2015-10-21 詹森药业有限公司 作为组蛋白去乙酰化酶抑制剂的吡啶和嘧啶衍生物
UA96436C2 (ru) * 2006-01-20 2011-11-10 Тиботек Фармасьютикелз Лтд. Долгосрочное лечение вич-инфекции
MX2008012577A (es) 2006-03-30 2008-10-10 Tibotec Pharm Ltd Pirimidinas sustituidas con 5-(hidroximetileno y aminometileno) que inhiben el virus de inmunodeficiencia humana.
WO2007113254A1 (en) 2006-03-30 2007-10-11 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-amido substituted pyrimidines
AU2016219555B2 (en) * 2006-06-23 2017-08-10 Janssen Sciences Ireland Uc Aqueous suspensions of TMC278
CN101478950B (zh) * 2006-06-23 2013-02-06 泰博特克药品有限公司 Tmc278的水性悬浮液
AU2014200819B2 (en) * 2006-06-23 2016-05-26 Janssen Sciences Ireland Uc Aqueous suspensions of TMC278
WO2008058285A2 (en) 2006-11-09 2008-05-15 Ardea Biosciences, Inc. 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors
BRPI0722384A2 (pt) 2006-12-08 2012-06-12 Irm Llc compostos inibidores de proteÍna quinase, composiÇÕes contendo os mesmos bem como seus usos
ES2550152T3 (es) 2006-12-13 2015-11-04 F. Hoffmann-La Roche Ag Derivados de 2-(piperidin-4-il)-4-fenoxi-o fenilamino-pirimidina como inhibidores no nucleósidos de transcriptasa inversa
CA2674185C (en) 2006-12-29 2017-02-28 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5,6-substituted pyrimidines
KR20090094073A (ko) 2006-12-29 2009-09-03 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 억제하는 6-치환된 피리미딘
AU2008210455A1 (en) 2007-01-31 2008-08-07 Vertex Pharmaceuticals Incorporated 2-aminopyridine derivatives useful as kinase inhibitors
TWI494133B (zh) 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
BRPI0810411B8 (pt) 2007-04-18 2021-05-25 Pfizer Prod Inc derivados de sulfonil amida para o tratamento de crescimento celular anormal, seu sos, bem como composição farmacêutica
ES2542153T3 (es) 2007-05-30 2015-07-31 F. Hoffmann-La Roche Ag Inhibidores no nucleósidos de la transcriptasa inversa
KR101294731B1 (ko) * 2007-06-04 2013-08-16 삼성디스플레이 주식회사 어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
WO2009007441A2 (en) * 2007-07-12 2009-01-15 Tibotec Pharmaceuticals Ltd. Crystalline form of (e) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile
CN101407476B (zh) * 2007-10-12 2012-07-18 中国人民解放军军事医学科学院毒物药物研究所 作为非核苷类hiv逆转录酶抑制剂的间二芳烃-多取代苯胺类化合物、其制备方法及用途
CN103058944B (zh) 2007-11-27 2015-08-05 亚德生化公司 调节血液尿酸水平的化合物
CA2709176C (en) 2007-12-14 2013-02-05 Ardea Biosciences, Inc. Reverse transcriptase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
NZ590784A (en) 2008-07-23 2012-12-21 Vertex Pharma Pyrazolopyridine kinase inhibitors
AU2009274023A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
EP2313372B1 (en) * 2008-08-06 2013-04-10 Vertex Pharmaceuticals Incorporated Aminopyridine kinase inhibitors
CN101717364B (zh) * 2008-10-09 2014-08-13 中国人民解放军军事医学科学院毒物药物研究所 作为hiv逆转录酶抑制剂的吡啶类化合物及其制备方法和用途
US8933106B2 (en) 2008-10-09 2015-01-13 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China 2-(4-substituted phenylamino) polysubstituted pyridine compounds as inhibitors of non-nucleoside HIV reverse transcriptase, preparation methods and uses thereof
EP2181991A1 (en) 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
US20110256206A1 (en) 2008-12-24 2011-10-20 Schachter Deborah M Implantable devices for treating hiv
JP5918693B2 (ja) 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｅｇｆｒ阻害剤及び疾患の治療方法
CA2760705A1 (en) 2009-05-06 2010-11-11 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
AU2011209726A1 (en) 2010-01-27 2012-08-09 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
CN102869663A (zh) 2010-01-27 2013-01-09 沃泰克斯药物股份有限公司 吡唑并吡嗪激酶抑制剂
KR101964923B1 (ko) 2010-01-27 2019-04-02 비이브 헬쓰케어 컴퍼니 항바이러스 치료
JP2013518114A (ja) 2010-01-27 2013-05-20 バーテックス ファーマシューティカルズ インコーポレイテッド ピラゾロピリミジンキナーゼ阻害剤
US20140018379A1 (en) * 2010-02-18 2014-01-16 Concert Pharmaceuticals Inc. Pyrimidine derivatives
US8367315B2 (en) * 2010-03-05 2013-02-05 Adan Rios Inactivation of reverse transcriptases by azido-diarylpyrimidines
AU2011289604C1 (en) 2010-08-10 2016-04-21 Celgene Avilomics Research, Inc. Besylate salt of a BTK inhibitor
JP5956999B2 (ja) 2010-11-01 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ヘテロアリール化合物およびその使用
NZ609957A (en) 2010-11-01 2015-08-28 Celgene Avilomics Res Inc Heterocyclic compounds and uses thereof
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
ES2665013T3 (es) 2010-11-10 2018-04-24 Celgene Car Llc Inhibidores de EGFR selectivos de mutante y usos de los mismos
PE20211657A1 (es) 2010-11-19 2021-08-24 Gilead Sciences Inc Composiciones terapeuticas que comprenden rilpivirina hcl y tenofovir disoproxil fumarato
WO2012125993A1 (en) 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Solid state forms of rilpivirine base, and rilipivirine salts
WO2012147091A2 (en) 2011-04-25 2012-11-01 Hetero Research Foundation Process for rilpivirine
JP6038151B2 (ja) 2011-08-30 2016-12-07 シーエイチディーアイ ファウンデーション，インコーポレーテッド キヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法
US9233935B2 (en) * 2011-09-16 2016-01-12 Hetero Research Foundation Rilpivirine hydrochloride
US9364476B2 (en) 2011-10-28 2016-06-14 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
EP2628732A1 (en) 2012-02-20 2013-08-21 Sandoz AG Novel crystalline form of rilpivirine hydrochloride
EP2604593A1 (en) 2011-12-14 2013-06-19 Sandoz AG Polymorph of Rilpivirine hydrochloride and its use as antiviral
WO2013087794A1 (en) 2011-12-14 2013-06-20 Sandoz Ag Polymorph of rilpivirine hydrochloride and its use as antiviral
CA2866857C (en) 2012-03-15 2021-03-09 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
CN108658873B (zh) 2012-03-15 2021-09-14 西建卡尔有限责任公司 表皮生长因子受体激酶抑制剂的固体形式
WO2013153162A1 (en) 2012-04-11 2013-10-17 Sandoz Ag Polymorph of rilpivirine hydrochloride
WO2013153161A2 (en) 2012-04-11 2013-10-17 Sandoz Ag Novel polymorph of rilpivirine hydrochloride
WO2013179105A1 (en) * 2012-06-01 2013-12-05 Laurus Labs Private Limited Improved process for preparation of rilpivirine and pharmaceutically acceptable salts thereof
US9139535B2 (en) * 2012-07-12 2015-09-22 Hetero Research Foundation Process for rilpivirine using novel intermediate
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
WO2014100748A1 (en) 2012-12-21 2014-06-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2014124230A2 (en) 2013-02-08 2014-08-14 Celgene Avilomics Research, Inc. Erk inhibitors and uses thereof
US9914709B2 (en) 2013-06-21 2018-03-13 Yale University Compositions and methods of treating HIV-1 infections using same
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2016011316A1 (en) 2014-07-17 2016-01-21 Chdi Foundation, Inc. Methods and compositions for treating hiv-related disorders
ES2741785T3 (es) 2014-08-13 2020-02-12 Celgene Car Llc Formas y composiciones de un inhibidor de ERK
SG11201702379TA (en) 2014-09-26 2017-04-27 Glaxosmithkline Ip No 2 Ltd Long acting pharmaceutical compositions
CZ201532A3 (cs) 2015-01-21 2015-02-25 Zentiva, K.S. Způsob výroby vysoce čistého Rilpivirinu a jeho solí
CN104926829A (zh) * 2015-06-08 2015-09-23 山东大学 一种噻吩并嘧啶类衍生物及其制备方法和应用
ES2925246T3 (es) 2015-06-30 2022-10-14 Gilead Sciences Inc Formulaciones farmacéuticas que comprenden tenofovir y emtricitabina
CZ2015579A3 (cs) 2015-08-27 2017-03-08 Zentiva, K.S. Krystalická forma A Rilpivirin Adipátu a způsob její přípravy
CN106187916B (zh) * 2016-07-04 2018-08-21 宜昌人福药业有限责任公司 一种有效去除利匹韦林异构体的方法
US11065198B2 (en) 2016-10-24 2021-07-20 Janssen Sciences Ireland Unlimited Company Dispersible compositions
CN106749203B (zh) * 2016-11-28 2020-04-10 洛阳聚慧医药科技有限公司 一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用
CN106588696B (zh) * 2016-12-08 2018-12-25 西北师范大学 一种反式α,β-不饱和腈类化合物的制备方法
CN106905244B (zh) * 2017-02-27 2019-08-16 武汉工程大学 二芳基嘧啶-二酮酸类杂合型hiv-1抑制剂及其制备方法
KR102722927B1 (ko) 2017-06-30 2024-10-28 비이브 헬쓰케어 컴퍼니 조합물 및 이의 용도 및 치료
CR20210175A (es) 2018-09-18 2021-06-01 Nikang Therapeutics Inc Derivados de anillo tricíclico condensado como inhibidores de la fosfatasa de homología a src 2 (shp2)
CN109293581B (zh) * 2018-09-21 2020-03-27 宜昌人福药业有限责任公司 一种制备盐酸利匹韦林异构体z和杂质x的方法及杂质x作为杀虫剂在农业中的应用
WO2020084142A1 (en) 2018-10-25 2020-04-30 Minakem Process for the preparation of rilpivirine
US20210000823A1 (en) * 2019-07-03 2021-01-07 Janssen Sciences Ireland Unlimited Company Methods of treating hiv
CN110526873B (zh) * 2019-08-15 2022-09-16 复旦大学 氰乙烯基取代的苯并二芳基嘧啶类化合物及其制备方法和用途
JP2023503403A (ja) 2019-11-29 2023-01-30 シピオ ライフ サイエンシズ リミテッド リルピビリンを含む組成物及び腫瘍又は癌を治療するためのその使用
CN111004215B (zh) * 2019-12-22 2022-08-09 华北理工大学 2,4-取代嘧啶类衍生物及其制备方法和在制备抗肿瘤药物中的应用
CN111217833B (zh) * 2020-02-21 2021-03-16 山东大学 噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用
WO2022000019A1 (en) * 2020-06-30 2022-01-06 University Of South Australia New therapeutic use of rilpivirine
CN112028836B (zh) * 2020-09-09 2021-12-07 山东大学 一种含有六元氮杂环的二芳基嘧啶类衍生物及其制备方法与应用
CN112010810B (zh) * 2020-09-09 2024-01-30 瑞阳制药股份有限公司 一锅法制备高纯度利匹韦林中间体的方法
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine
TW202233192A (zh) 2020-11-17 2022-09-01 愛爾蘭商健生科學愛爾蘭無限公司 Hiv感染之治療或預防
CN112546969B (zh) * 2020-12-07 2022-12-23 安徽贝克制药股份有限公司 催化加氢连续生产装置和利托那韦中间体的制备方法
CN112778214A (zh) * 2021-01-13 2021-05-11 安徽贝克联合制药有限公司 用于合成利匹韦林的中间体、其合成方法和利匹韦林的合成方法
CN113105394A (zh) * 2021-03-08 2021-07-13 复旦大学 一种含芳杂环结构的联苯二芳基嘧啶类衍生物及其制备方法和应用
CN113461666A (zh) * 2021-05-06 2021-10-01 复旦大学 含芳杂环结构的联苯二芳基甲基嘧啶衍生物及其制备方法
CN113845515A (zh) * 2021-09-03 2021-12-28 复旦大学 一种含芳杂环结构的二甲基联苯二芳基嘧啶类衍生物及其制备方法和应用
EP4433026A1 (en) 2021-11-17 2024-09-25 Janssen Sciences Ireland Unlimited Company Dissolution test
TW202408580A (zh) 2022-04-22 2024-03-01 愛爾蘭商健生科學愛爾蘭無限公司 冷凍乾燥組成物(二)
US20250268896A1 (en) 2022-04-22 2025-08-28 Janssen Sciences Ireland Unlimited Company Liquid compositions
TW202408527A (zh) 2022-05-17 2024-03-01 愛爾蘭商健生科學愛爾蘭無限公司 治療或預防hiv感染(二)
TW202408526A (zh) 2022-05-17 2024-03-01 愛爾蘭商健生科學愛爾蘭無限公司 治療或預防hiv感染(一)
CN115490642B (zh) * 2022-09-21 2024-11-15 山东大学 一种含醚键的二芳基嘧啶类化合物及其制备方法与应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3953398A (en) * 1970-07-20 1976-04-27 The Goodyear Tire & Rubber Company Age resistant polymeric compositions
JPS63159316A (ja) * 1977-11-28 1988-07-02 アルキユサル　インコーポレーテツド　ピーテイワイ　リミテツド 中性銅結合体を含む抗炎症組成物
EP0002341B1 (en) * 1977-11-28 1982-01-20 Barry Boettcher Complexes of bivalent copper, methods of preparation thereof and compositions containing said complexes
JPS5879920A (ja) * 1981-11-09 1983-05-13 Kanegafuchi Chem Ind Co Ltd 血小板凝集阻害剤
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5691364A (en) 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
NZ322907A (en) 1995-11-23 1998-12-23 Janssen Pharmaceutica Nv Solid mixtures of cyclodextrins prepared via melt-extrusion
TW429256B (en) 1995-12-27 2001-04-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
JP3990808B2 (ja) * 1998-03-26 2007-10-17 Ｔｄｋ株式会社 非水電解質電池用電極の製造方法
DE69943247D1 (de) * 1998-03-27 2011-04-14 Janssen Pharmaceutica Nv HIV hemmende Pyrimidin Derivate
EP0945447A1 (en) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
TR200002760T2 (tr) * 1998-03-27 2000-12-21 Janssen Pharmaceutica N.V. HIV engelleyici pirimidin türevleri
JP2000035628A (ja) * 1998-07-16 2000-02-02 Konica Corp ハロゲン化銀写真感光材料
EP1107957B1 (en) * 1998-08-29 2006-10-18 AstraZeneca AB Pyrimidine compounds
WO2000027825A1 (en) * 1998-11-10 2000-05-18 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines
PL350651A1 (en) 1999-03-09 2003-01-27 Upjohn Co 4-oxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents
RU2260592C9 (ru) 1999-04-15 2017-04-07 Бристол-Маерс Сквибб Ко. Циклические ингибиторы протеинтирозинкиназ
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
DE19945982A1 (de) 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
PL207590B1 (pl) * 1999-09-24 2011-01-31 Janssen Pharmaceutica Nv Cząstka stanowiąca dyspersję stałą oraz postać dawkowania, sposób ich otrzymywania i zastosowanie
HUP0301117A3 (en) * 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
WO2001085700A2 (en) 2000-05-08 2001-11-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
ES2559273T3 (es) 2000-05-08 2016-02-11 Janssen Pharmaceutica Nv Profármacos de pirimidinas que inhiben la replicación del VIH
US6596729B2 (en) 2000-07-20 2003-07-22 Bristol-Myers Squibb Company Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
MXPA03007883A (es) * 2001-03-02 2003-12-04 Smithkline Beecham Corp Benzofenonas como inhibidores de transcriptasa inversa.
US6949544B2 (en) * 2001-03-29 2005-09-27 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
US8101629B2 (en) * 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
CA2457526A1 (en) * 2001-08-29 2003-03-13 Umd, Inc. Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
MXPA04010778A (es) * 2002-05-03 2005-03-07 Janssen Pharmaceutica Nv Microemulsiones polimericas.
CN101481356B (zh) 2002-08-09 2012-07-11 詹森药业有限公司 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
WO2004050068A1 (en) 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
US20070021449A1 (en) 2003-02-07 2007-01-25 Jan Heeres Pyrimidine derivatives for the prevention of hiv infection
WO2011103559A1 (en) * 2010-02-22 2011-08-25 Nektar Therapeutics Oligomer modified diaromatic substituted compounds

Also Published As

Publication number Publication date
US7125879B2 (en) 2006-10-24
FR12C0035I2 (fr) 2016-02-12
AU2002329238B2 (en) 2008-01-24
EA006656B1 (ru) 2006-02-24
HU230192B1 (hu) 2015-09-28
CN100509801C (zh) 2009-07-08
HUS1500055I1 (hu) 2016-03-29
KR20040023645A (ko) 2004-03-18
HRP20192051A2 (hr) 2020-03-06
CN101816658A (zh) 2010-09-01
FR22C1036I1 (fr) 2022-09-09
BR122015032641B1 (pt) 2022-03-03
HUP0401346A2 (hu) 2004-12-28
CY2022024I1 (el) 2023-01-05
BR0211909A (pt) 2004-08-24
JP5539927B2 (ja) 2014-07-02
HK1145449A1 (en) 2011-04-21
DE122012000038I1 (de) 2012-09-20
FR12C0035I1 (forum.php) 2012-06-22
CN1541215A (zh) 2004-10-27
NO327639B1 (no) 2009-09-07
FR12C0036I1 (forum.php) 2012-06-29
CY2012012I2 (el) 2015-08-05
CY2022024I2 (el) 2023-01-05
CA2452217A1 (en) 2003-02-27
JP5247661B2 (ja) 2013-07-24
EP2298761A1 (en) 2011-03-23
DK1419152T3 (da) 2011-10-24
ZA200401159B (en) 2005-07-27
AP1610A (en) 2006-05-08
US10611732B2 (en) 2020-04-07
EP1419152A1 (en) 2004-05-19
ES2923581T3 (es) 2022-09-28
HUS2200038I1 (hu) 2022-08-28
SI1419152T1 (sl) 2011-11-30
KR100969273B1 (ko) 2010-08-20
UA78221C2 (uk) 2007-03-15
HK1070066A1 (zh) 2005-06-10
LTC3808743I2 (forum.php) 2023-04-25
CA2452217C (en) 2009-06-16
JP2011236221A (ja) 2011-11-24
JP2011225589A (ja) 2011-11-10
NO20040633L (no) 2004-03-12
CY2012013I1 (el) 2015-08-05
BR122015023612B8 (pt) 2021-05-25
PL216398B1 (pl) 2014-03-31
BE2022C531I2 (forum.php) 2022-08-09
US8080551B2 (en) 2011-12-20
US20180244632A1 (en) 2018-08-30
US20170320835A1 (en) 2017-11-09
US9580392B2 (en) 2017-02-28
HRP20040096A2 (en) 2004-06-30
EP3808743A1 (en) 2021-04-21
PA8552901A1 (es) 2003-02-28
EA200400304A1 (ru) 2004-08-26
JP4838396B2 (ja) 2011-12-14
IL160328A0 (en) 2004-07-25
ES2799408T3 (es) 2020-12-17
BR122015023612B1 (pt) 2021-01-19
LTPA2022515I1 (forum.php) 2022-08-25
NO337142B1 (no) 2016-02-01
SI3808743T1 (sl) 2022-09-30
OA12652A (en) 2006-06-15
CY1112331T1 (el) 2015-08-05
KR20070101409A (ko) 2007-10-16
HU231274B1 (hu) 2022-07-28
HUP0401346A3 (en) 2009-03-02
IL160328A (en) 2011-01-31
AP2004002993A0 (en) 2004-03-31
US20040198739A1 (en) 2004-10-07
DK3808743T3 (da) 2022-08-01
JO3429B1 (ar) 2019-10-20
NO20083770L (no) 2004-03-12
WO2003016306A1 (en) 2003-02-27
NO2012010I1 (no) 2012-06-18
MXPA04001401A (es) 2004-05-27
JP2005507380A (ja) 2005-03-17
LU92008I2 (fr) 2012-07-24
US20140343006A1 (en) 2014-11-20
US10370340B2 (en) 2019-08-06
EP1419152B1 (en) 2011-07-27
NO2012010I2 (no) 2013-09-02
ATE517891T1 (de) 2011-08-15
US9981919B2 (en) 2018-05-29
BE2012C022I2 (forum.php) 2022-01-12
HUS1500051I1 (hu) 2018-05-28
CN101816658B (zh) 2014-08-27
BRPI0211909B8 (pt) 2021-05-25
KR100817453B1 (ko) 2008-03-27
HRP20040096B1 (hr) 2013-06-30
US20060252764A1 (en) 2006-11-09
PT1419152E (pt) 2011-10-11
BE2012C020I2 (forum.php) 2021-07-19
MY189572A (en) 2022-02-17
EG24684A (en) 2010-05-05
AR036387A1 (es) 2004-09-08
US20190322628A1 (en) 2019-10-24
HRP20120265B1 (hr) 2019-11-29
HRP20192051B1 (hr) 2022-05-27
US20170121292A1 (en) 2017-05-04
JP2010077140A (ja) 2010-04-08
FR12C0036I2 (fr) 2016-05-06
PL402388A1 (pl) 2013-04-02
LT3808743T (lt) 2022-08-10
LU92001I2 (fr) 2012-07-16
HRP20120265A2 (hr) 2012-05-31
CY2012012I1 (el) 2015-08-05
EP2298761B1 (en) 2020-03-25
US20120076835A1 (en) 2012-03-29
EP3808743B1 (en) 2022-07-20
ES2368996T3 (es) 2011-11-24
BRPI0211909B1 (pt) 2018-05-29
AU2002329238C1 (en) 2008-08-28
CY2012013I2 (el) 2015-08-05
PL368270A1 (en) 2005-03-21

Similar Documents

Publication Publication Date Title
US10611732B2 (en) HIV replication inhibiting pyrimidines
AU2002329238A1 (en) HIV inhibiting pyrimidines derivatives
AU2005271161B2 (en) HIV inhibiting 1,2,4-triazin-6-one derivatives
EP1668011A2 (en) Hiv replication inhibiting purine derivatives

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 09 AUG 2022 BY CPA GLOBAL

Effective date: 20140903

EXPY Patent expired